Genetic Signatures

Genetic Signatures Asset Growth

The Year-over-Year Total Asset Growth of Genetic Signatures (GSS.AX) as of Oct 28, 2026 is -29.61 %. In the previous year, Year-over-Year Total Asset Growth was -18.81 % — a change of 57.40% (lower).

Asset Growth

-29.61 %

YoY

57.40%

Last updated:

Year-over-Year Total Asset Growth of Genetic Signatures is 2026 -29.61 % . Year-over-Year Total Asset Growth of Genetic Signatures was 2025 -18.81 % . It decreases by 57.40% lower compared to the previous year.

The Genetic Signatures Asset Growth history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Asset Growth
Date
Asset Growth
Jan 1, 2019
-16.97 AUD
Jan 1, 2020
309.85 AUD
Jan 1, 2021
8.71 AUD
Jan 1, 2022
10.37 AUD
Jan 1, 2023
-17.73 AUD
Jan 1, 2024
37.10 AUD
Jan 1, 2025
-18.81 AUD
Jan 1, 2026
-29.61 AUD
The Genetic Signatures Asset Growth history
YEARAsset GrowthYoY
-29.61 %+57.40%
-18.81 %-150.70%
37.10 %-309.28%
-17.73 %-270.89%
10.37 %+19.06%
8.71 %-97.19%
309.85 %-1,926.28%
-16.97 %-2.21%
-17.35 %-108.83%
196.40 %-933.97%
-23.55 %-55.45%
-52.86 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Genetic Signatures Stock analysis

What does Genetic Signatures do? Genetic Signatures Ltd. develops real-time PCR based products for infectious disease detection, focusing on the 3base platform technology. The company commercializes its MDx 3base platform, enabling high-volume hospitals and pathology labs to screen for infectious pathogens with high specificity and rapid results. Products under the EasyScreen brand include the EasyScreen Pan-Enteric Detection Kit, EasyScreen STI Genital Pathogen Detection, and EasyScreen Viral Meningitis Detection Kit, sold into diagnostic and research marketplaces. The firm targets hospitals and pathology laboratories as key buyers of its diagnostic solutions. Its products are designed for routine detection of infectious diseases, with the EasyScreen suite addressing specific pathogen categories like enteric, STI, and viral meningitis. The company focuses on research and commercialization of genetic signature identification for disease detection, leveraging its 3base platform for high-throughput screening. Genetic Signatures Ltd. generates revenue through the sale of its real-time PCR based products under the EasyScreen brand. The MDx 3base platform technology is central to its commercial strategy, providing a solution for rapid, specific pathogen screening in clinical settings. The company's product portfolio includes multiple kits targeting different infectious disease categories, all sold into the diagnostic and research markets. Genetic Signatures is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Genetic Signatures stock

Year-over-Year Total Asset Growth of Genetic Signatures is -29.61 % in 2026.

On Eulerpool you can find the complete historical development of Year-over-Year Total Asset Growth Genetic Signatures since 2006 – with annual values, charts, and detailed analysis.

Asset growth measures the percentage change in total assets. Rapid asset growth may indicate expansion but can also correlate with lower future returns.

To evaluate Year-over-Year Total Asset Growth's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Year-over-Year Total Asset Growth.

Year-over-Year Total Asset Growth's is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Year-over-Year Total Asset Growth's Genetic Signatures historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Growth — Genetic Signatures

All Key Metrics — Genetic Signatures